Koszorúér-betegség: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PCSK9 14
• SGLT2 12
• APOE 0
• GLP-1 4
• NLRP3 2
• PPAR 0
• IL-6 2
• NRF2 0
• CD40 0
• AKT 0
• VEGF 0
• TNF 1
• PI3K 0
• SIRT1 0
• TLR4 0
• TP53 0
• HMGB1 0
• STAT3 0
• HIF-1 0
• AMPK 0
• IL-1 1
• JAK 0
• MMP-9 0
• STING 1
• ACE2 0
• ERK 0
• GIP 1
• mTOR 0
• PD-1 0
• BDNF 0
• COX-2 0
• CXCR4 1
• DPP-4 0
• FGFR 0
• HER2 0
• IL-17 1
• MAPK 0
• PTEN 0
• TREM2 0
• YAP 0
• ABL1 0
• ALK 0
• ANGPTL3 0
• APP 0
• BACE1 0
• BCL-2 0
• BRAF 0
• BTK 0
• CCR5 0
• CGRP 0
• CTLA-4 0
• CTNNB1 0
• EZH2 0
• FOXP3 0
• FTO 0
• G6PD 0
• GPX4 0
• HSP90 0
• IL-4 1
• LRRK2 0

3057 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• U.S. Department of Veterans Affairs · IK1

  Evaluating hypertension care delivery in Veterans with rheumatoid arthritis to improve cardiovascular disease prevention

  Durham Va Medical Center· Durham, Egyesült Államok· until 2028. okt.

• U.S. Department of Veterans Affairs · IK6

  ISRM Research Career Scientist Award Application

  Veterans Health Administration· Pittsburgh, Egyesült Államok· until 2031. szept.

• U.S. Department of Veterans Affairs · I01

  Nitrated oleic acid-mediated angiogenesis and long-term functional recovery after ischemic stroke

  Veterans Health Administration· Pittsburgh, Egyesült Államok· until 2030. szept.

• NIH NINR · R01

  Discovery of Symptom Burdens and Their Associations with Health Outcomes among People Living with HIV

  University of Texas Hlth Sci Ctr Houston· Houston, Egyesült Államok· 402 355 USD awarded in fiscal year 2026· until 2030. jún.

• NIH NLM · R21

  MACE-Alert: An Artificial Intelligence based Assessment and Triage of Undifferentiated Chest Pain

  University of California, San Diego· La Jolla, Egyesült Államok· 216 000 USD awarded in fiscal year 2026· until 2028. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unmasking the Perivascular Adipose Tissue's Role in Diabetic Vascular Disease From Molecular Clues to Clinical Impact (IMAPERFAT)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 236 340 EUR· until 2029. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Delineating and eradicating cardiovascular inflammageing (DEFLAME)

  Technische Universiteit Eindhoven· Eindhoven, Hollandia· EU contribution 2 500 000 EUR· until 2032. febr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Predicting Female-Predominant Cardiovascular Dissections via multi-scale Hormonal, Imaging, and Biomechanical Integration (DISSEX)

  Aarhus Universitet· Aarhus C, Dánia· EU contribution 1 499 585 EUR· until 2032. febr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  DEVELOPMENT OF A NANOHYBRID SYSTEM BASED WEARABLE MICROFLUIDIC PHOTOELECTROCHEMICAL SENSOR FOR THE ON-DEMAND cTnI DETECTION (NANOPEC)

  Kauno Technologijos Universitetas· Kaunas, Litvánia· EU contribution 196 976 EUR· until 2029. jan.· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Socio-Environmental Determinants of Health in Small States (SEEDS)

  Universita Ta Malta· Msida, Málta· EU contribution 205 314 EUR· until 2029. jan.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 2033 running projects, newest first. Listed amounts together: 1,2 Mrd USD + 236,0 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Comparison of Short Versus 12 Months Prasugrel Plus Aspirin in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Intervention and Everolimus-eluting Stents

  NCT06718179· Odense University Hospital· Frissítve: 2026. okt. 22.

  “Insufficient drug supply (prasugrel)”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Is Our Microbiome a Predictor of Cardiac Risk

  NCT02013284· Mayo Clinic· Frissítve: 2026. okt. 20.

  “Reorganizing study personnel and funding”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Heart Disease

  NCT05147766· The Foundation for Orthopaedics and Regenerative Medicine· Frissítve: 2026. okt. 20.

  “Inadequate treatment response observed in preliminary data did not justify enrolling further study participants”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  3rd Generation Resorbable Magnesium Scaffolds vs Biodegradable Polymer Stents in NSTE/ACS

  NCT06409117· Konstantinos Toutouzas· Frissítve: 2026. okt. 19.

  “No funding”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL

  NCT07625306· Novartis Pharmaceuticals· Frissítve: 2026. okt. 14.

  “Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System

  NCT06071702· Medinol Ltd.· Frissítve: 2026. okt. 9.

  “Study was not initiated in any site. Sponsor decided not to start the study”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)

  NCT07449325· VahatiCor, Inc.· Frissítve: 2026. szept. 25.

  “Study suspended to implement a protocol change”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  YN001-004 in Patients With Coronary Atherosclerosis in Australia

  NCT06700720· Beijing Inno Medicine Co., Ltd.· Frissítve: 2026. szept. 23.

  “The study was terminated at the request of the Sponsor.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Clinical and Biochemical Effects of a Defined Plant-Based Diet on Heart Disease

  NCT06994624· Georgia State University· Frissítve: 2026. szept. 2.

  “Death of lead PI”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Comparative Outcomes of Mammary Artery Harvesting: Infection, Occlusion Rates and Thoracic Pain Assessment

  NCT07720661· Hamilton Health Sciences Corporation· Frissítve: 2026. júl. 28.

  “Registered too early. Completing the vanguard first which is registered separately.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Aerobic Exercise-induced Effect on Cardiorespiratory Fitness, Endothelial Function, and Brain-derived Neurotrophic Factor in Patients With Ischaemic Heart Disease

  NCT06788275· Instituto de Investigación Sanitaria y Biomédica de Alicante· Forrás

• Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI

  NCT06678074· Implicit Bioscience· Forrás

• Health Coaching for Patients With Cardiovascular Disease

  NCT06904144· Ohio State University· Forrás

• Optical Coherence Tomography in Acute Vessel Evaluation

  NCT07422688· Aarhus University Hospital Skejby· Forrás

• Bogalusa Heart Study

  NCT00005129· Tulane University· Forrás

• A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease

  NCT07839936· Verve Therapeutics, Inc.· Forrás

• EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

  NCT05284747· Amgen· Forrás

• Effect of the SCOT-HEART 2 Trial on Lifestyle.

  NCT04156061· University of Edinburgh· Forrás

• Telegram Messenger Support for Smoking Cessation After Heart Attack

  NCT07230249· ITMO University· Forrás

• ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY

  NCT07545512· University Hospital, Clermont-Ferrand· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 14
• Organoids 1
• Mendelian Randomization Analysis 136
• CRISPR-Cas Systems 4
• Gene Expression Profiling 48
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Exome Sequencing 6
• Proteomics 68
• Metabolomics 41
• Mass Spectrometry 5
• Flow Cytometry 26
• Immunohistochemistry 12
• Positron-Emission Tomography 64
• Magnetic Resonance Imaging 66
• Machine Learning 163
• Deep Learning 85
• Cohort Studies 405
• Genome-Wide Association Study 163

• dioscRi enables transferable prediction of clinical outcomes in multi-parameter cytometry data.

  Nat Commun, 2026. aug.

• Whole Blood Flow Cytometric Quantification of Tissue Factor-Positive Platelets: A Harmonized Multicenter Workflow.

  J Vis Exp, 2026. aug.

• Platelet FcɣRIIa Expression Refines Clinical Risk Assessment After Myocardial Infarction.

  Catheter Cardiovasc Interv, 2026. jún.

• Reduction in circulating endothelial progenitor cells caused by obstructive sleep apnea-related hypoxemia and its association with the severity of coronary artery disease.

  Coron Artery Dis, 2026. jan.

• Effect of Atorvastatin Therapy on the Level of CD34+CD133+CD309+ Endothelial Progenitor Cells in Patients with Coronary Heart Disease.

  Bull Exp Biol Med, 2017. jún.

• Atorvastatin inhibits the immediate-early response gene EGR1 and improves the functional profile of CD4+T-lymphocytes in acute coronary syndromes.

  Oncotarget, 2017. márc.

• Atorvastatin promotes human monocyte differentiation toward alternative M2 macrophages through p38 mitogen-activated protein kinase-dependent peroxisome proliferator-activated receptor γ activation.

  Int Immunopharmacol, 2015. márc.

• The effect of rosuvastatin on platelet-leukocyte interactions in the setting of acute coronary syndrome.

  J Am Coll Cardiol, 2015. jan.

• Effects of simvastatin/ezetimibe on microparticles, endothelial progenitor cells and platelet aggregation in subjects with coronary heart disease under antiplatelet therapy.

  Braz J Med Biol Res, 2014. máj.

• Effect of vitamin D analogues on acute cardiorenal syndrome: a laboratory rat model.

  Isr Med Assoc J, 2013. nov.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.